

R E V I E W

Genetic syndromes with localized subcutaneous fat tissue accumulation

Vincenza Precone¹, Shila Barati¹, Stefano Paolacci², Marzia Salgarello³, Giuseppe Visconti³, Stefano Gentileschi³, Giulia Guerrì², Lucilla Gagliardi⁴, Barbara Aquilanti⁴, Giuseppina Matera⁴, Valeria Velluti⁴, Giacinto Abele Donato Miggiano^{4,5}, Karen L. Herbst⁶, Matteo Bertelli¹

¹MAGI Euregio, Bolzano, Italy; ²MAGI's Lab, Rovereto (TN), Italy; ³Centre for Surgical Treatment of Lymphedema, Plastic Surgery Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy; ⁴UOC Nutrizione Clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; ⁵Centro di Ricerche in Nutrizione Umana, Università Cattolica Sacro Cuore, Rome, Italy; ⁶Department of Medicine, University of Arizona, Tucson, Arizona, USA

Summary. Syndromes with localized accumulation of subcutaneous fatty tissue belong to a group of genetically and phenotypically heterogeneous disorders. These diseases may show some common signs, such as nodular fat, symmetrical fat masses, obesity, fatigue, lymphedema and symmetrical lipomas (painful or otherwise). Other symptoms may be specific for the different clinical entities, enabling correct differential diagnosis. Disorders belonging to this spectrum are lipedema, generalized diffuse or nodular forms of Dercum disease, localized nodular Dercum disease and multiple symmetric lipomatosis. Here we summarize the genes involved in syndromes with localized accumulation of subcutaneous fat and the test we use for genetic analysis. (www.actabiomedica.it)

Key words: lipedema, Dercum disease, lipomatosis

Lipedema is an underdiagnosed chronic debilitating disease characterized by bruising, pain and excess subcutaneous fat affecting the lower and/or upper limbs of women during or after periods of hormonal change, especially puberty (1). The first guidelines on lipedema were proposed in Germany in 2015, and again in 2017 using the international classification of function, disability and health (2-4). Lipedema can easily be confused with obesity, but is distinguished by primarily affecting the lower limbs and upper extremities; the fat deposits do not reduce with a low-calorie diet and body mass index is normal (5). Lipedema can also be confused with lymphedema, but is always bilateral, whereas lymphedema can be unilateral or bilateral; pain and bruising are absent in lymphedema while lipedema patients are negative for Stemmer sign (6). The prevalence of lipedema has been reported to be 1-9/100,000 (7). Lipedema can

be considered a component of a spectrum of diseases characterized by dysregulated proliferation of adipose tissue and pain: generalized diffuse form of Dercum disease (painful pearl-sized nodular subcutaneous adipose tissue throughout the body); generalized nodular form of Dercum disease (large painful nodules on the arms, trunk, and thighs); lipedema (localized form of painful fat with pearl-sized nodular fat and larger masses on the limbs); localized nodular form of Dercum disease (localized around joints); Madelung disease or multiple symmetric lipomatosis (nodular fat and lipomas on the upper part of the body (8,9)). Genetic testing that includes all genes known to be involved in syndromes with localized accumulation of subcutaneous fat is useful for confirming diagnosis, and for differential diagnosis, recurrence risk evaluation and prenatal diagnosis in families with a known mutation (10).

Syndromes with localized subcutaneous fat accumulation can have autosomal dominant or autosomal recessive inheritance (Table 1). Pathogenic variants may be missense, nonsense, splicing or small indels.

MAGI uses a multi-gene NGS panel to detect nucleotide variations in coding exons and flanking introns of the genes listed in Table 1.

Table 1. Genes associated with various forms of localized accumulation of subcutaneous fat

.Gene	OMIM gene	Disease	OMIM disease	Inheritance	Function
<i>POU1F1</i>	173110	Combined pituitary hormone deficiency 1 (1 family with lipedema)	613038	AD	Regulation of expression of growth hormone, prolactin, thyroid-stimulating hormone
<i>NSD1</i>	606681	Sotos syndrome 1 (1 case with lipedema)	117550	AD	Androgen receptor transactivation
<i>ALDH18A1</i>	138250	Cutis laxa, type III (abnormal fat pad, buttocks, upper thighs (some patients))	616603, 219150	AD, AR	De novo biosynthesis of proline, ornithine, arginine
<i>PALB2</i>	610355	Multiple subcutaneous familial lipomatosis (1 case)	/	AD	DNA repair
<i>TBL1XR1</i>	608628	Pierpont syndrome	602342	AD	Essential transcription activation mediated by nuclear receptors
<i>MFN2</i>	608507	Madelung disease	151800	AR	Mitochondrial membrane protein necessary for mitochondrial fusion and maintenance of mitochondrial network
<i>LMNA</i>	150330	FPLD2	151660	AD	Nuclear assembly, chromatin organization, nuclear membrane and telomere dynamics
<i>PPARG</i>	601487	FPLD3	604367	AD	Master regulator of adipocyte differentiation
<i>PLIN1</i>	170290	FPLD4	613877	AD	Coating of lipid storage droplets in adipocytes
<i>CIDEA</i>	612120	FPLD5	615238	AR	Regulation of lipid droplet enlargement by restricting lipolysis, favoring storage
<i>LIPE</i>	151750	FPLD6	615980	AR	Hydrolysis of stored triglycerides to free fatty acids
<i>AKT2</i>	164731	FPLD	/	AD	Key-mediator of insulin receptor
<i>ADRA2A</i>	104210	Atypical FPLD	/	AD	Fundamental for regulation of neurotransmitter release from sympathetic nerves and adrenergic neurons in CNS

FPLD=familial partial lipodystrophy; AD=autosomal dominant; AR=autosomal recessive; CNS = central nervous system.

Conclusions

We created a NGS panel to detect nucleotide variations in coding exons and flanking regions of all the genes associated with localized accumulation of subcutaneous fat. When this suspects is present we perform the analysis of all the genes present in this short article.

In order to have a high diagnostic yield, we developed a NGS test that reaches an analytical sensitivity (proportion of true positives) and an analytical specificity (proportion of true negatives) of $\geq 99\%$ (coverage depth $\geq 10x$).

Conflict of interest: Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article

References

1. Wold LE, Hines EA, Allen EV. Lipedema of the legs; a syndrome characterized by fat legs and edema. *Ann Intern Med* 1951; 34: 1243-50.
2. Halk AB, Damstra RJ. First Dutch guidelines on lipedema using the international classification of functioning, disability and health. *Phlebology* 2017; 32: 152-9.
3. Reich-Schupke S, Schmeller W, Brauer WJ, et al. S1 guidelines: lipedema. *J Dtsch Dermatol Ges* 2017; 15: 758-67.
4. Hardy D, Williams A. Best practice guidelines for the management of lipoedema. *Br J Community Nurs* 2017; 22: S44-8.
5. Warren AG, Janz BA, Borud LJ, Slavin SA. Evaluation and management of the fat leg syndrome. *Plast Reconstr Surg* 2007; 119: 9-15.
6. Forner-Cordero I, Szolnoky G, Forner-Cordero A, Kemény L. Lipedema: an overview of its clinical manifestations, diagnosis and treatment of the disproportional fatty deposition syndrome - systematic review. *Clin Obes* 2012; 2: 86-95.
7. <https://www.orpha.net/consor/cgi-bin/index.php>
8. Hansson E, Svensson H, Brorson H. Review of Dercum's disease and proposal of diagnostic criteria, diagnostic methods, classification and management. *Orphanet J Rare Dis* 2012; 7: 23.
9. Beltran K, Herbst KL. Differentiating lipedema and Dercum's disease. *Int J Obes* 2017; 41: 240-5.
10. Herbst KL. Rare adipose disorders (RADs) masquerading as obesity. *Acta Pharmacol Sin* 2012; 33: 155-72.

Received: 5 August 2019

Accepted: 5 September 2019

Correspondence:

Stefano Paolacci

Via delle Maioliche 57/D - 38068 Rovereto (TN), Italy

E-mail: stefano.paolacci@assomagi.org